RT Journal Article
SR Electronic
T1 An immune dysfunction score for stratification of patients with acute infection based on whole blood gene expression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.17.22272427
DO 10.1101/2022.03.17.22272427
A1 Cano-Gamez, Eddie
A1 Burnham, Katie L
A1 Goh, Cyndi
A1 Malick, Zunaira H
A1 Kwok, Andrew
A1 Smith, David A
A1 Peters-Sengers, Hessel
A1 Antcliffe, David
A1 GAinS Investigators
A1 McKechnie, Stuart
A1 Scicluna, Brendon P
A1 van der Poll, Tom
A1 Gordon, Anthony C
A1 Hinds, Charles J
A1 Davenport, Emma E
A1 Knight, Julian C
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.17.22272427.abstract
AB Dysregulated host responses to infection can lead to organ dysfunction and sepsis, causing millions of deaths globally each year. To alleviate this burden, improved prognostication and biomarkers of response are urgently needed. We investigated the use of whole blood transcriptomics for stratification of patients with severe infection by integrating data from 3,149 samples of sepsis patients and healthy individuals into a gene expression reference map. We used this map to derive a quantitative sepsis response signature (SRSq) score reflective of immune dysfunction and predictive of clinical outcomes, which can be estimated using a 19-gene signature. Finally, we built a machine learning framework, SepstratifieR, to deploy SRSq in sepsis, H1N1 influenza, and COVID-19, demonstrating clinically relevant stratification across diseases and revealing the physiological alterations linking immune dysregulation to mortality. Our method enables early identification of individuals with dysfunctional immune profiles, thus bringing us closer to precision medicine in infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in whole, or in part, by the Medical Research Council (MR/V002503/1), Wellcome Trust Investigator Award (204969/Z/16/Z), Wellcome Trust core funding to the Wellcome Sanger Institute (Grant number WT206194), Wellcome Trust Grants (090532/Z/09/Z and 203141/Z/16/Z) to core facilities of the Wellcome Centre for Human Genetics, and NIHR Oxford Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this work was given by the following UK Research Ethics Committees: Scotland A Research Ethics Committee (05/MRE00/38), Berkshire Research Ethics Committee (08/H0505/78), and Oxfordshire Research Ethics Committee (06/Q1605/55). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets used in this study are publicly available, with accession numbers listed in the manuscript. All data produced in the present study are available upon request and will be made publicly available upon publication. https://github.com/jknightlab/SepstratifieR